Imfinzi (durvalumab) has been granted breakthrough therapy status by the FDA for the treatment of lung cancer in certain cases, reports Healio.

“For patients who have not progressed following chemoradiation therapy, the only current option is active monitoring,” Sean Bohen, executive vice president of global medicines development and chief medical officer at AstraZeneca, said in a company-issued press release.

“Unfortunately, for the majority of patients, their cancer will progress to metastatic disease, typically within 12 months. Imfinzi is the first immuno-oncology medicine to show a clinically significant benefit in this earlier, nonmetastatic setting so, following the breakthrough designation, we hope to bring it to patients as soon as possible.”